O
OrbiMed Portfolio holdings
AUM
$3.98B
This Quarter Return
+6.96%
1 Year Return
+13.05%
3 Year Return
+159.74%
5 Year Return
+207.27%
10 Year Return
+1,027.33%
AUM
$7.91B
AUM Growth
+$7.91B
(+12%)
Cap. Flow
+$959M
Cap. Flow
% of AUM
12.12%
Top 10 Holdings %
Top 10 Hldgs %
33.78%
Holding
159
New
26
Increased
22
Reduced
25
Closed
17
Top Buys
| 1 |
Prelude Therapeutics
PRLD
|
$470M |
| 2 |
PMV Pharmaceuticals
PMVP
|
$260M |
| 3 |
AFIB
Acutus Medical, Inc. Common Stock
AFIB
|
$163M |
| 4 |
CalciMedica
CALC
|
$56.9M |
| 5 |
Theravance Biopharma
TBPH
|
$54.2M |
Top Sells
| 1 |
Ascendis Pharma
ASND
|
$128M |
| 2 |
Cigna
CI
|
$82.5M |
| 3 |
Natera
NTRA
|
$81.6M |
| 4 |
Glaukos
GKOS
|
$46.5M |
| 5 |
Alector
ALEC
|
$34.2M |
Sector Composition
| 1 | Healthcare | 98.49% |
| 2 | Financials | 0.64% |
| 3 | Technology | 0.57% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
76
Arcturus Therapeutics
ARCT
$462M
| $26.5M | 0.33% | 618,586 +379,400 | +159% | +$16.3M |
|
77
Standard BioTools
LAB
$481M
| $26.4M | 0.33% | 3,553,703 +646,603 | +22% | +$4.8M |
|
78
Mersana Therapeutics
MRSN
$36.5M
| $24.7M | 0.31% | 1,328,852 -581,156 | -30% | -$10.8M |
|
79
NextCure
NXTC
$13.5M
| $23.9M | 0.3% | 2,711,013 | – | – |
|
80
Amgen
AMGN
$155B
| $23.3M | 0.29% | 91,500 | – | – |
|
81
Novo Nordisk
NVO
$251B
| $22.9M | 0.29% | 330,000 | – | – |
|
|
NMTR
82
DELISTED
9 Meters Biopharma, Inc. Common Stock
NMTR
| $20.5M | 0.26% | 25,716,755 | – | – |
|
|
CTIC
83
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
| $20.5M | 0.26% | 9,520,600 | – | – |
|
84
Alcon
ALC
$39.5B
| $19.9M | 0.25% | 351,380 | – | – |
|
|
ISEE
85
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $19.2M | 0.24% | 3,411,806 +161,806 | +5% | +$913K |
|
|
OSH
86
DELISTED
Oak Street Health, Inc.
OSH
| $17.9M | 0.22% | +334,400 | New | +$17.9M |
|
|
TRIL
87
DELISTED
Trillium Therapeutics Inc.
TRIL
| $17.8M | 0.22% | 1,252,600 +41,600 | +3% | +$591K |
|
88
Heron Therapeutics
HRTX
$207M
| $17.7M | 0.22% | 1,191,846 +531,426 | +80% | +$7.88M |
|
|
FLXN
89
DELISTED
Flexion Therapeutics, Inc.
FLXN
| $17.5M | 0.22% | 1,684,000 | – | – |
|
90
Teva Pharmaceuticals
TEVA
$21.1B
| $17.4M | 0.22% | 1,935,200 | – | – |
|
91
Guardant Health
GH
$8.41B
| $17.2M | 0.22% | +154,300 | New | +$17.2M |
|
|
PAND
92
DELISTED
Pandion Therapeutics Inc. Common Stock
PAND
| $17M | 0.21% | +1,480,940 | New | +$17M |
|
93
Forte Biosciences
FBRX
$137M
| $16.5M | 0.21% | 340,480 -609,836 | -64% | -$29.6M |
|
94
Syndax Pharmaceuticals
SNDX
$1.41B
| $16.1M | 0.2% | 1,094,100 | – | – |
|
95
Zymeworks
ZYME
$1.12B
| $15.9M | 0.2% | 341,102 -241,200 | -41% | -$11.2M |
|
|
SRRA
96
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
| $15.8M | 0.2% | 1,477,320 | – | – |
|
97
Relay Therapeutics
RLAY
$619M
| $14.9M | 0.19% | +350,000 | New | +$14.9M |
|
98
BiomX
PHGE
$14.3M
| $14.7M | 0.18% | 2,313,489 | – | – |
|
99
Larimar Therapeutics
LRMR
$310M
| $13.4M | 0.17% | 886,560 -47,400 | -5% | -$719K |
|
|
OTIC
100
DELISTED
Otonomy, Inc.
OTIC
| $13.2M | 0.17% | +3,250,000 | New | +$13.2M |
|